IRD Opus Genetics, Inc.: Pangali EV/EBITDA

Opus Genetics Inc (IRD) designs gene therapies for vision, outsourcing the entire production of viral vectors to third-party contractors due to a lack of in-house capacity. High patent barriers and the complexity of microsurgery make this segment virtually inaccessible to new entrants. The share price retrospective on GURU.Markets shows an EV/EBITDA of 0.00, while patient base growth is limited by the rarity of mutations and FDA decisions.

This indicator compares the enterprise value (EV) of the business with its operating profit before depreciation and amortization, allowing for an asset valuation that accounts for debt load and taxes. By analyzing the historical EV/EBITDA ratio of the business, an investor can identify asset undervaluation, which for Opus Genetics Inc (IRD) is offset by absolute pricing power and inelastic demand for its unique gene therapy.